Citius Pharmaceuticals Inc expected to post a loss of 2 cents a share - Earnings Preview

Citius Pharmaceuticals

18/12/2023 11:03

* Citius Pharmaceuticals Inc  CTXR.OQ   CTXR.O  is expected
to show no change in quarterly revenue when it reports 
results on December 20 (estimated) for the period ending June
30 2023
    * 
    * ​LSEG's mean analyst estimate for Citius Pharmaceuticals
Inc is
for a loss of 2 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $4.00​, above​ its last closing price
of $0.80. ​​​

This summary was machine generated December 18 at 11:02 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)